Day: October 14, 2024

Daix (France), Long Island City (New York, United States), October 14, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the filing, for the six-month period ended June 30, 2024 of its Half-Year Report (the “2024 Half-Year Report”) with the French financial markets authority, “Autorité des Marchés Financiers” (“AMF”). The Company’s condensed consolidated interim financial statements for the six-month period ended June 30, 2024 were prepared under the responsibility of the Board of Directors and...

                                        October 14, 2024 – 7:45 a.m. CET Regulated information – Contains inside information Fiona Lam appointed as CFO for the Agfa-Gevaert Group Mortsel, Belgium – October 14, 2024 – 7:45 a.m. CET On October 15, 2024, Fiona Lam joins the Agfa-Gevaert Group as Chief Financial Officer and member of the Executive Committee. Current CFO Dirk De Man has decided to take a step back due to health reasons. CEO Pascal Juéry commented: “I am delighted to welcome Fiona Lam to our leadership team. I am convinced that Fiona’s extensive, international experience in transformation in diverse IT and industrial environments will prove to be invaluable to Agfa, as we are currently refocusing our organization around a number of future-oriented, promising activities. I also wish to express my gratitude to...

Positive data confirm Evrysdi efficacy and safety in children first treated pre-symptomatically before six weeks of age, with most achieving motor milestones similar to children without SMA All children were able to swallow and feed orally, with none requiring permanent ventilation Evrysdi is the only non-invasive SMA therapy and is approved in over 100 countries, with more than 16,000 people with SMA treated globallyBasel, 14 October 2024 – Roche (SIX: RO, ROG; OTCQX: RHHBY) presented positive two-year data from the ongoing RAINBOWFISH study at the 29th World Muscle Society (WMS) Congress, 8-12 October, 2024, assessing the efficacy and safety of Evrysdi® (risdiplam) in children with SMA who were treated pre-symptomatically as infants before six weeks of age (n=23). The study found the majority of children achieved key motor...

Dubai and Amsterdam, 14 October 2024: VEON Ltd. (Nasdaq: VEON, Euronext Amsterdam: VEON), a global digital operator (“VEON” or the “Group”), today announces that its Board of Directors has approved a plan to move the VEON Group headquarters from Amsterdam to Dubai, United Arab Emirates, where VEON’s expanding operational hub has been located since early 2022. With the move of its headquarters to its hub in the Dubai International Financial Centre (DIFC), the Group will become the largest Nasdaq-listed company with its Group headquarters in Dubai, which is also home to Nasdaq Dubai. “Our decision to relocate VEON’s headquarters to Dubai reflects the strategic realignment of our focus with closer proximity to our key markets. This move positions us to capitalize on the vast opportunities Dubai offers, including its proximity to our operations,...

Oslo, 14 October 2024 – DNO ASA, the Norwegian oil and gas operator, will publish its Q3 2024 operating and interim financial results on 7 November at 07:00 (CET). A videoconference call with executive management will follow at 14:00 (CET). Today the Company provides an update on production, sales volumes and other key information for the quarter. Volumes (boepd)Gross operated production Q3 2024 Q2 2024 Q3 2023Kurdistan 84,212 79,783 25,984North Sea – – –       Net entitlement production Q3 2024 Q2 2024 Q3 2023Kurdistan 17,607 17,167 9,897North Sea 11,236 16,321 14,288       Sales Q3 2024 Q2 2024 Q3 2023Kurdistan 17,607 17,167 9,897North Sea 15,306 12,871 15,749       Equity accounted production (net) Q3 2024 Q2 2024 Q3 2023      Côte d’Ivoire         2,843 3,256 3,373Selected...

DENVER, Colo., Oct. 13, 2024 (GLOBE NEWSWIRE) — Illumination Brands, formerly known as CBD Global Sciences Inc. (“CBDN”); (the “Company”), announces its proposed plans to pay off all secured and unsecured creditors of CBDN, with any remaining shares/funds distributed as a return of capital to shareholders proportionately, as of the record date of such event. CBDN was delisted from trading on the Canadian Securities Exchange (“CSE”) on December 5, 2023. The Company had been under a Cease Trade Order (“CTO”) since July 7, 2022, and has not traded for over two years. Despite its attempt to shift its focus away from the CBD industry and into more profitable sectors, CBDN has continued to face significant cash flow challenges. Efforts to lift the CTO consumed hundreds of thousands of dollars and countless hours, yet CBDN...